Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02750514 · ClinicalTrials.gov registry record · Phase 2
An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 2
- Development phase
- 295
- Enrollment target
NCT02750514: Clinical Trial Phase 2 study, sponsored by Bristol-Myers Squibb.
NCT02750514 is a Phase 2 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 295 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (122% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02750514, a Phase 2 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 295 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether Nivolumab, in combination with other therapies, is effective in patients with advanced Non-Small Cell lung cancer
Primary Outcome
ORR is defined as the percentage of participants whose confirmed best overall response (BOR) is either a complete response (CR) or partial response (PR). BOR was assessed by investigator per RECIST1.1. Results are presented by study track. Track 1 = participants naive for prior immuno-oncology (IO) therapy and PD-L1 positive Track 2 = participants naive for prior immuno-oncology (IO) therapy and PD-L1 negative Track 3 = participants with prior anti-PD-1/PD-L1 therapy Track 4 = participants naiv
Interventions
- BIOLOGICAL Nivolumab
- DRUG Dasatinib
- BIOLOGICAL Ipilimumab
- BIOLOGICAL Relatlimab
- DRUG BMS-986205
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 295 participants |
| Start Date | 2016-05-09 |
| Est. Completion | 2020-01-29 |
| Phase | Phase 2 |
Why NCT02750514 stopped before completion
NCT02750514 is an interventional study that assigns participants to a tested intervention. The registered 295 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (122% higher).
The record links to 0 conditions, and to 5 interventions - of which Nivolumab is the first listed.
NCT02750514 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02750514 about?
NCT02750514 is a clinical study titled "An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer". The purpose of this study is to determine whether Nivolumab, in combination with other therapies, is effective in patients with advanced Non-Small Cell lung cancer
What is the current status of trial NCT02750514?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 295 participants. The study started on 2016-05-09. Estimated completion is 2020-01-29.
What interventions are being tested in trial NCT02750514?
The interventions under investigation include: Nivolumab (BIOLOGICAL), Dasatinib (DRUG), Ipilimumab (BIOLOGICAL), Relatlimab (BIOLOGICAL), BMS-986205 (DRUG).
Who is sponsoring clinical trial NCT02750514?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02750514's enrollment target sits among peer trials
295 189th of 2000 higher than 1,811 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05201781 · 295 participants · Phase 4
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- NCT06004245 · 295 participants · Phase 1
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
- NCT06494111 · 295 participants · Phase 2
Systemic Therapy of Open-label Prophylactic Pravastatin or Pentoxifylline/Tocopherol Prevention of Lymphedema Advancing to Eventual Fibrosis: an Interventional Registry-embedded Bayesian Randomized Trial for Radiation Sequelae (STOP4-LATE-FIBROSE)
- NCT07020221 · 295 participants · Phase 1
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI